Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : INHL - Inhale Therapeutics - Pulmonary Insulin! -- Ignore unavailable to you. Want to Upgrade?

To: Rick Costantino who wrote (63)	1/6/1998 11:31:00 AM
From: Rick Costantino	Respond to of 225

Inhale was up to $32 this morning! Here's some news I found..another collaboration with Lilly! I wonder which protein it is? Lilly and Inhale Enter Into Development and License Agreement for Pulmonary Delivery Technology for Second Protein Business Wire - January 06, 1998 08:46 %INHALE %LILLY INHL LLY %CALIFORNIA %INDIANA %PHARMACEUTICAL %MEDICINE %BIOTECHNOLOGY %PRODUCT V%BW P%BW Jump to first matched term SAN CARLOS, Calif.--(BW HealthWire)--Jan. 6, 1998--Eli Lilly and Co. (NYSE:LLY) and Inhale Therapeutic Systems (NASDAQ:INHL) announced today that they have entered into a collaborative agreement to develop pulmonary delivery for an unspecified protein product based on Inhale's deep-lung delivery system for macromolecules. This is the second collaborative agreement between the two companies. Under the terms of the agreement, Inhale will receive funding up to $20 million of research, development and milestone payments. Lilly will receive global commercialization rights for the pulmonary delivery of the products with Inhale receiving royalties on any marketed products. Inhale will manufacture packaged powders for and supply inhalation devices to Lilly. "We are pleased to expand our relationship with Lilly to develop a second pulmonary delivery product," said Rob Chess, Inhale CEO and president. Inhale and Lilly are also working on pulmonary delivery for a selected osteoporosis product. "Inhale has proven to be among the leaders in the field of aerosolized delivery of proteins," said Richard DiMarchi, Lilly vice president of research, technologies and proteins. "This additional collaboration builds upon our mutual experiences in the initial project that began nearly one year ago." Both Inhale and Lilly will dedicate resources to the collaboration. Lilly will lead the clinical trial effort. Inhale will develop dry powder formulations and apply its powder processing, powder packaging and inhalation device for use with the drug. Inhale, recently relocated to San Carlos, is developing a pulmonary delivery system to enable a wide range of drugs, including macromolecules, to be delivered by the pulmonary route for systemic and local lung indications. The company currently has six drugs in clinical trials using its delivery system and has feasibility and development partnerships with several pharmaceutical and biotechnology companies. Lilly is a global research-based pharmaceutical corporation headquartered in Indianapolis that is dedicated to creating and delivering innovative pharmaceutical-based health care solutions which enable people to live longer, healthier and more active lives. This release may contain forward-looking statements that reflect management's current views of future events and operations. These forward-looking statements are based on assumptions, external factors, uncertainties and other risks that are detailed in Inhale's SEC reports, including its Form 10-K for the year ending Dec. 31, 1996. Actual results could differ materially from these forward-looking statements. CONTACT: Inhale Joyce Strand, 650/631-3138 or Lilly James Kappel, 317/276-5795